Metraipolis › archive › dc_1e709ea54b87

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53 — Europe PMC PMID:42505221

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42505221
DOI
10.3390/curroncol33070419
License (as archived)
solo-consultazione
Archived
2026-10-18T07:58:37.396Z
SHA-256 of the archived text
594d6a28257dce5965a1a4a6b99592e5821d5692cc86f0ad596667bd50bc8144
Stable URL of this page
https://metraipolis.com/documento/dc_1e709ea54b87

How to cite

Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53 — Europe PMC PMID:42505221 — Europe PMC (en), https://europepmc.org/article/MED/42505221 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1e709ea54b87 (Metraipolis archive dc_1e709ea54b87, sha256 594d6a28257dce5965a1a4a6b99592e5821d5692cc86f0ad596667bd50bc8144)
BibTeX
@misc{dc1e709ea54b87,
  title = {Impact of High-Risk Mutations and Treatment Intensity in Accelerated-Phase Blast-Phase MPN Without Adverse-Risk Karyotype and TP53 — Europe PMC PMID:42505221},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42505221},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1e709ea54b87; sha256 594d6a28257dce5965a1a4a6b99592e5821d5692cc86f0ad596667bd50bc8144},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42505221. Agents can read the archived copy with the MCP tool read_document.